Nicholas J. Sarlis

Biography

Dr. Nicholas J. (Nick) Sarlis is the Chief Medical Officer and Senior VP of SELLAS Life Science Group, Ltd,, and an experienced clinician as well as recognized expert in the global pharmaceutical market with a focus in oncology and hematology. As former Vice President and Head of Global Medical Affairs at Incyte Corporation, Dr. Sarlis led a global team supporting targeted and immuno-oncology pipeline agents. He led the integrated medical affairs plan to support the late clinical development of the innovative immuno-enhancer epacadostat , the original indoleamine 2,3-dioxygenase type-1 (IDO1) inhibitor. Dr. Sarlis and his team supported the successive launches of ruxolitinib (Jakafi®) – the original Janus kinase (JAK) inhibitor- in myelofibrosis and polycythemia vera. Prior to his time at Incyte, Dr. Sarlis held senior positions at Sanofi Aventis having led medical teams for launching key oncology and cancer supportive care products in both the United States and the European Union. He received his medical degree and doctorate from the University of Athens, and a Ph.D. in Molecular Biology/ Neuroendocrinology from the University of London. Dr. Sarlis is board certified by the American Board of Internal Medicine, and previously served as senior faculty at the National Institutes of Health and Associate Professor at MD Anderson Cancer Center. Dr. Sarlis has published more than 130 articles (peer-reviewed papers, textbook chapters and monographs). He has received numerous awards, being most recently nominated as the recipient of the 2016 Annual Award by Cancer Research and Treatment Fund (CR&T). He is a Fellow of the American College of Physicians (FACP), the American College of Endocrinology (FACE), the Royal Society of Medicine (UK; FRSM), and the Molecular Medicine Society (FMMS). Dr. Nicholas J. (Nick) Sarlis is the Chief Medical Officer and Senior VP of SELLAS Life Science Group, Ltd,, and an experienced clinician as well as recognized expert in the global pharmaceutical market with a focus in oncology and hematology. As former Vice President and Head of Global Medical Affairs at Incyte Corporation, Dr. Sarlis led a global team supporting targeted and immuno-oncology pipeline agents. He led the integrated medical affairs plan to support the late clinical development of the innovative immuno-enhancer epacadostat , the original indoleamine 2,3-dioxygenase type-1 (IDO1) inhibitor. Dr. Sarlis and his team supported the successive launches of ruxolitinib (Jakafi®) – the original Janus kinase (JAK) inhibitor- in myelofibrosis and polycythemia vera. Prior to his time at Incyte, Dr. Sarlis held senior positions at Sanofi Aventis having led medical teams for launching key oncology and cancer supportive care products in both the United States and the European Union. He received his medical degree and doctorate from the University of Athens, and a Ph.D. in Molecular Biology/ Neuroendocrinology from the University of London. Dr. Sarlis is board certified by the American Board of Internal Medicine, and previously served as senior faculty at the National Institutes of Health and Associate Professor at MD Anderson Cancer Center. Dr. Sarlis has published more than 130 articles (peer-reviewed papers, textbook chapters and monographs). He has received numerous awards, being most recently nominated as the recipient of the 2016 Annual Award by Cancer Research and Treatment Fund (CR&T). He is a Fellow of the American College of Physicians (FACP), the American College of Endocrinology (FACE), the Royal Society of Medicine (UK; FRSM), and the Molecular Medicine Society (FMMS).

Research Interest

Pharmaceutical Sciences